CIP2A and breast cancer: In current study, CIP2A silencing leads to decreased cell viability in MCF-7 cells in addition to doxorubicin-mediated effects, suggesting that targeting CIP2A may represent a potential therapeutic strategy to treat breast cancer patients who developed resistance to doxorubicin.